Baidu
map

J Sex Med:公开性取向,让我们更健康

2015-03-22 MedSci MedSci原创

近期Mor Z 等人对以色列女性进行了一项横断面研究。比较女同性恋+双性恋(LB)和异性恋女性(HW)之间健康状况、健康行为/保健行为、性取向(SO)的披露、避免卫生保健等健康方面的差异。该研究通过分布在网站、公共场所的匿名问卷调查进行。

近期Mor Z 等人对以色列女性进行了一项横断面研究。比较女同性恋+双性恋(LB)和异性恋女性(HW)之间健康状况、健康行为/保健行为、性取向(SO)的披露、避免卫生保健等健康方面的差异。该研究通过分布在网站、公共场所的匿名问卷调查进行。

该研究于2012年共收集到1858份完成的问卷,其中681(34.4%)为女同性恋,242(13.5%)为双性恋,余下937(52.1%)为异性恋女性。




研究结果显示,LB比HW有更多的单身、更容易出现药物/酒精滥用、吸烟、饮食失调、首次性交时间更早等情况。与所有女性相比,女同性恋体育活动更少,对自身体重满意度更高,而双性恋有更冒险的性行为,比如更多的口头或身体虐待。LB较之HW,有更多的急诊,更多的精神病方面咨询,更少的宫颈涂片检查。通过多变量分析得出,女同性恋很少去咨询妇科医生,对医疗健康系统满意度低;但是双性恋,其咨询全科医生/妇科医生更少,满意度更低。女同性恋比双性恋更可能乐意告知医生其性取向,并且不会对坦诚性取向而感到羞愧沮丧。对性取向保密的人其主观健康状况可能更差。同时对性取向保密的女性是双性恋的可能性更大。

研究结果表明,女同性恋+双性恋(LB)比异性恋女性(HW)更少的进行医疗健康活动,导致不能满足其医疗需求。公开性取向与更好的医疗服务使用率有关,将得到更好的健康结局,尤其是在双性恋人群中。医疗服务人群应该对LB独特的医疗需求进行专门培训,改善沟通交流技巧,鼓励其公开性取向,收获健康。

原始出处:

Mor Z1, Eick U, Wagner Kolasko G, Zviely-Efrat I, Makadon H, Davidovitch N.Health Status, Behavior, and Care of Lesbian and Bisexual Women in Israel.J Sex Med. 2015 Mar 9. doi: 10.1111/jsm.12850. [Epub ahead of print]

本文系Medsci原创编译整理!转载需要先获得授权,并附原文链接。谢谢!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=49559, encodeId=0c80495598d, content=。, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 19:54:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377484, encodeId=5d9613e7484e4, content=<a href='/topic/show?id=58b452660d9' target=_blank style='color:#2F92EE;'>#性取向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52660, encryptionId=58b452660d9, topicName=性取向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f5a410, createdName=zxxiang, createdTime=Tue Mar 24 11:20:00 CST 2015, time=2015-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606443, encodeId=21701606443f8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Mar 24 11:20:00 CST 2015, time=2015-03-24, status=1, ipAttribution=)]
    2015-12-27 忠诚向上

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=49559, encodeId=0c80495598d, content=。, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 19:54:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377484, encodeId=5d9613e7484e4, content=<a href='/topic/show?id=58b452660d9' target=_blank style='color:#2F92EE;'>#性取向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52660, encryptionId=58b452660d9, topicName=性取向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f5a410, createdName=zxxiang, createdTime=Tue Mar 24 11:20:00 CST 2015, time=2015-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606443, encodeId=21701606443f8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Mar 24 11:20:00 CST 2015, time=2015-03-24, status=1, ipAttribution=)]
    2015-03-24 zxxiang
  3. [GetPortalCommentsPageByObjectIdResponse(id=49559, encodeId=0c80495598d, content=。, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 19:54:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377484, encodeId=5d9613e7484e4, content=<a href='/topic/show?id=58b452660d9' target=_blank style='color:#2F92EE;'>#性取向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52660, encryptionId=58b452660d9, topicName=性取向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f5a410, createdName=zxxiang, createdTime=Tue Mar 24 11:20:00 CST 2015, time=2015-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606443, encodeId=21701606443f8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Mar 24 11:20:00 CST 2015, time=2015-03-24, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map